Existing RA treatments target 11 previously identified as therapeutic target for RA, including TNFRSF1A, IL1R1, IL6ST, CD40, TGF-β1, IRAK1, SH2B3, AIM2, IL2RA, PTPN2, and FLT3, all of which are involved in cytokine signaling and immune regulation. Here, PTPN2 is linked to rheumatoid arthritis.